Copley Scientific introduces new, upgraded breath simulators for inhaled product testing

14 Nov 2017

The upgraded BRS simulators make it even easier to apply specified inhalation profiles during OIP testing.

Copley Scientific has launched new, advanced breath simulators - the BRS 2100 and BRS 3100, for orally inhaled product (OIP) development and testing. In recent years, in response to regulatory and pharmacopoeial changes, and the drive to ensure closer correlation between in vivo and in vitro performance, scientists have increasingly incorporated breath simulators into their testing methods. Now, the upgraded BRS simulators from Copley Scientific make it even easier to apply specified inhalation profiles during OIP testing.

Copley Scientific introduces new, upgraded breath simulators for inhaled product testing
a test set-up optimised for improved IVIVCs, incorporating the BRS3100 and the adult Alberta Idealised Throat.

The BRS 2100 is ideally configured for testing nebulisers and metered dose inhalers (MDIs) with spacers/valved holding chambers (VHC) in accordance with US Pharmacopeia Chapter <1601> and Chapter <1602> respectively; the latter having only recently been released. The BRS 2100 has a maximum volume of 900 mL making it ideally suited to the low-volume, tidal breathing applications required by these chapters. The BRS 3100 offers greater volumes (500 mL up to 5000 mL) and the increased power (maximum flow rate of 240 L/min) needed for generating profiles typical of patients using MDIs and dry powder inhalers (DPIs) under forced inhalation conditions, helping to improve in vitro-in vivo correlations (IVIVCs).

As well as generating the ‘standard’ breathing profiles needed to measure delivered dose uniformity (DDU) according to pharmacopoeial requirements, namely: neonate, infant, child, and adult, for nebulisers and MDIs with spacers/VHCs, both the BRS 2100 and 3100 are designed to generate user-defined, patient-derived breathing profiles that more closely mimic real-world clinical situations. Importantly, the standard profiles can be used as a base and edited for development studies, adjusting the selected square, sinusoidal or triangular pattern, the tidal volume and the number, duration and timing of each breathing cycle, for example. For even more control, users can build and then save their own unique breathing profiles to simulate any desired pattern or breathing technique, as may have been recorded in clinic. Both breath simulators can be used for DDU applications or combined with a cascade impactor, using a mixing inlet, for aerodynamic particle size distribution (APSD) studies under more patient realistic conditions.

Compared with prior BRS 2000 and 3000 models, the BRS 2100 and BRS 3100 both feature an upgraded Quad-Core processor, increased RAM, improved Windows 10 operating system, and redesigned software, as part of the embedded, on-board computer. Significant gains in data processing speed and usability are the result. The instruments are also more flexible; for example, flow rates can be displayed in mL/s or L/min, and it is now easier to simulate uncoordinated product use, in the case of VHCs, by synchronising sampling with the exhalation portion of a breathing profile. In addition, the mechanics have been advanced – with improved motor, piston and cylinder performance enabling the more rigorous testing of high-resistance inhalers, and the creation of more powerful inhalation profiles. Additional peripherals and external data transfer are improved by the increased number of USB ports.

Mark Copley, Sales Director at Copley Scientific, comments: “In recent years, breath simulators have become a core piece of OIP testing equipment. This is partly because of the need to achieve better in vitro-in vivo relationships to enhance product development, and also in response to changing regulatory guidance, which has been updated for greater clinical relevance. Significant progress was made when the previous generation of breath simulators was introduced and now, with our upgraded series of instruments, we are very pleased to be putting state-of-the-art tools once again into the hands of our users.”

Read More

Related tags

Market News

Related news

Spanish CDMO working ahead of EU serialisation deadline

Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

Read more 
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

5 Dec 2018

The financing will power the global commercial launch of the company's Fluidity One system.

Read more 
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

4 Dec 2018

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Read more 
India to have strongest global growth in 2019?

India to have strongest global growth in 2019?

4 Dec 2018

Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.

Read more 
Catalent to expand biologics packaging capabilities

Catalent to expand biologics packaging capabilities

3 Dec 2018

Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.

Read more 
Merck successfully divests Consumer Health

Merck successfully divests Consumer Health

2 Dec 2018

Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.

Read more 
Digital manufacturing is a top priority for life sciences

Digital manufacturing is a top priority for life sciences

29 Nov 2018

Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.

Read more 
NIH to evaluate effectiveness of male contraceptive skin gel

NIH to evaluate effectiveness of male contraceptive skin gel

28 Nov 2018

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Read more 
QPS expands US-based Phase I clinical trial capabilities

QPS expands US-based Phase I clinical trial capabilities

27 Nov 2018

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Read more 
Hikma announces injectable licensing agreement

Hikma announces injectable licensing agreement

27 Nov 2018

Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.

Read more